Dyslipidemia and Cardiovascular Prevention in the Elderly: A Balancebetween Benefits and Risks of Statin Treatment in a Specific Population Article Swipe
Vincenzo G. Fiore
,
Alessandra Barucca
,
Sonia Barraco
,
Domenico Triggiani
,
Daniele Tragni
,
Giuseppina Piazzolla
,
Vincenzo Triggiani
,
Giovanni Carbotta
,
Giuseppe Lisco
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.2174/1871530323666230428092828
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.2174/1871530323666230428092828
Introduction: Atherosclerotic Cardiovascular Diseases (CVD) are among the most relevant causes of morbidity and mortality worldwide, especially in aged people. Statins are one of the leading pharmacological interventions against atherosclerosis and are widely used to reduce the risk of occur-ring coronary artery diseases and related outcomes in both primary and secondary prevention. The management of chronic diseases is improved considerably over time, leading to an increase in life ex-pectancy despite heavier comorbidity-related burdens in the elderly. Aims: The paper focused on the role of statins in the management of atherosclerosis and related burdens in elderly patients. Results: Statins are essential in reducing the risk of CVD in secondary and primary prevention, partic-ularly in high-risk individuals. Guidelines encourage using specific algorithms with age-specific cut-offs to assess individual cardiovascular risk irrespective of baseline age, as the expansion of life expec-tancy produces favorable effects of statin treatment in those over 70. Discussion: Besides the estimation of baseline CV risk, a specific age-related assessment is also nec-essary before prescribing statin treatment in aged people focusing on frailty, potential pharmacological interactions due to polypharmacotherapy, cognitive impairment, and background chronic comorbidi-ties, such as diabetes mellitus. Before starting statin therapy, an accurate choice of type and dose of statins is needed as potential adverse events are more prevalent with high-dose than low-to-moderate-dose regimens and with lipophile than hydrophile statins (e.g., potential implication on intra-cerebral cholesterol metabolism). Conclusion: Despite possible adverse events, elderly patients should receive statins, when appropriate, to avoid the first occurrence of recurrent cardiovascular events and related burdens.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.2174/1871530323666230428092828
- OA Status
- green
- Cited By
- 5
- References
- 39
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4367553837
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4367553837Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.2174/1871530323666230428092828Digital Object Identifier
- Title
-
Dyslipidemia and Cardiovascular Prevention in the Elderly: A Balancebetween Benefits and Risks of Statin Treatment in a Specific PopulationWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-05-01Full publication date if available
- Authors
-
Vincenzo G. Fiore, Alessandra Barucca, Sonia Barraco, Domenico Triggiani, Daniele Tragni, Giuseppina Piazzolla, Vincenzo Triggiani, Giovanni Carbotta, Giuseppe LiscoList of authors in order
- Landing page
-
https://doi.org/10.2174/1871530323666230428092828Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://hdl.handle.net/11573/1691501Direct OA link when available
- Concepts
-
Medicine, Dyslipidemia, Statin, Adverse effect, Diabetes mellitus, Population, Comorbidity, Internal medicine, Primary prevention, Intensive care medicine, Disease, Environmental health, EndocrinologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 3, 2023: 2Per-year citation counts (last 5 years)
- References (count)
-
39Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4367553837 |
|---|---|
| doi | https://doi.org/10.2174/1871530323666230428092828 |
| ids.doi | https://doi.org/10.2174/1871530323666230428092828 |
| ids.openalex | https://openalex.org/W4367553837 |
| fwci | 2.51867801 |
| type | article |
| title | Dyslipidemia and Cardiovascular Prevention in the Elderly: A Balancebetween Benefits and Risks of Statin Treatment in a Specific Population |
| biblio.issue | 11 |
| biblio.volume | 23 |
| biblio.last_page | 1379 |
| biblio.first_page | 1371 |
| topics[0].id | https://openalex.org/T10394 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.98089998960495 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Lipoproteins and Cardiovascular Health |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.885759711265564 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778096610 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7622237801551819 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1476525 |
| concepts[1].display_name | Dyslipidemia |
| concepts[2].id | https://openalex.org/C2776839432 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6274682283401489 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q954845 |
| concepts[2].display_name | Statin |
| concepts[3].id | https://openalex.org/C197934379 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5955736637115479 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[3].display_name | Adverse effect |
| concepts[4].id | https://openalex.org/C555293320 |
| concepts[4].level | 2 |
| concepts[4].score | 0.58151775598526 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[4].display_name | Diabetes mellitus |
| concepts[5].id | https://openalex.org/C2908647359 |
| concepts[5].level | 2 |
| concepts[5].score | 0.48736244440078735 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[5].display_name | Population |
| concepts[6].id | https://openalex.org/C2779159551 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4774087965488434 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1414874 |
| concepts[6].display_name | Comorbidity |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4180557131767273 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C2993857929 |
| concepts[8].level | 3 |
| concepts[8].score | 0.41652822494506836 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1773974 |
| concepts[8].display_name | Primary prevention |
| concepts[9].id | https://openalex.org/C177713679 |
| concepts[9].level | 1 |
| concepts[9].score | 0.39244145154953003 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[9].display_name | Intensive care medicine |
| concepts[10].id | https://openalex.org/C2779134260 |
| concepts[10].level | 2 |
| concepts[10].score | 0.3135486841201782 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[10].display_name | Disease |
| concepts[11].id | https://openalex.org/C99454951 |
| concepts[11].level | 1 |
| concepts[11].score | 0.12626105546951294 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[11].display_name | Environmental health |
| concepts[12].id | https://openalex.org/C134018914 |
| concepts[12].level | 1 |
| concepts[12].score | 0.10663720965385437 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[12].display_name | Endocrinology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.885759711265564 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/dyslipidemia |
| keywords[1].score | 0.7622237801551819 |
| keywords[1].display_name | Dyslipidemia |
| keywords[2].id | https://openalex.org/keywords/statin |
| keywords[2].score | 0.6274682283401489 |
| keywords[2].display_name | Statin |
| keywords[3].id | https://openalex.org/keywords/adverse-effect |
| keywords[3].score | 0.5955736637115479 |
| keywords[3].display_name | Adverse effect |
| keywords[4].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[4].score | 0.58151775598526 |
| keywords[4].display_name | Diabetes mellitus |
| keywords[5].id | https://openalex.org/keywords/population |
| keywords[5].score | 0.48736244440078735 |
| keywords[5].display_name | Population |
| keywords[6].id | https://openalex.org/keywords/comorbidity |
| keywords[6].score | 0.4774087965488434 |
| keywords[6].display_name | Comorbidity |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.4180557131767273 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/primary-prevention |
| keywords[8].score | 0.41652822494506836 |
| keywords[8].display_name | Primary prevention |
| keywords[9].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[9].score | 0.39244145154953003 |
| keywords[9].display_name | Intensive care medicine |
| keywords[10].id | https://openalex.org/keywords/disease |
| keywords[10].score | 0.3135486841201782 |
| keywords[10].display_name | Disease |
| keywords[11].id | https://openalex.org/keywords/environmental-health |
| keywords[11].score | 0.12626105546951294 |
| keywords[11].display_name | Environmental health |
| keywords[12].id | https://openalex.org/keywords/endocrinology |
| keywords[12].score | 0.10663720965385437 |
| keywords[12].display_name | Endocrinology |
| language | en |
| locations[0].id | doi:10.2174/1871530323666230428092828 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S4210179974 |
| locations[0].source.issn | 1871-5303, 2212-3873 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1871-5303 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Endocrine Metabolic & Immune Disorders - Drug Targets |
| locations[0].source.host_organization | https://openalex.org/P4310320079 |
| locations[0].source.host_organization_name | Bentham Science Publishers |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320079 |
| locations[0].source.host_organization_lineage_names | Bentham Science Publishers |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Endocrine, Metabolic & Immune Disorders - Drug Targets |
| locations[0].landing_page_url | https://doi.org/10.2174/1871530323666230428092828 |
| locations[1].id | pmh:oai:iris.uniroma1.it:11573/1691501 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4377196107 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | IRIS Research product catalog (Sapienza University of Rome) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | info:eu-repo/semantics/article |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://hdl.handle.net/11573/1691501 |
| locations[2].id | pmh:oai:ricerca.uniba.it:11586/430532 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4377196296 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) |
| locations[2].source.host_organization | https://openalex.org/I5561750 |
| locations[2].source.host_organization_name | University of Bari Aldo Moro |
| locations[2].source.host_organization_lineage | https://openalex.org/I5561750 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://hdl.handle.net/11586/430532 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5102954915 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4865-5482 |
| authorships[0].author.display_name | Vincenzo G. Fiore |
| authorships[0].countries | IT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210157822 |
| authorships[0].affiliations[0].raw_affiliation_string | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[0].institutions[0].id | https://openalex.org/I4210157822 |
| authorships[0].institutions[0].ror | https://ror.org/05xcney74 |
| authorships[0].institutions[0].type | government |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210157822 |
| authorships[0].institutions[0].country_code | IT |
| authorships[0].institutions[0].display_name | Azienda Sanitaria Locale Roma 3 |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Vincenzo Fiore |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[1].author.id | https://openalex.org/A5027052887 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Alessandra Barucca |
| authorships[1].countries | IT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210157822 |
| authorships[1].affiliations[0].raw_affiliation_string | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[1].institutions[0].id | https://openalex.org/I4210157822 |
| authorships[1].institutions[0].ror | https://ror.org/05xcney74 |
| authorships[1].institutions[0].type | government |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210157822 |
| authorships[1].institutions[0].country_code | IT |
| authorships[1].institutions[0].display_name | Azienda Sanitaria Locale Roma 3 |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Alessandra Barucca |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[2].author.id | https://openalex.org/A5018068327 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Sonia Barraco |
| authorships[2].countries | IT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210157822 |
| authorships[2].affiliations[0].raw_affiliation_string | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[2].institutions[0].id | https://openalex.org/I4210157822 |
| authorships[2].institutions[0].ror | https://ror.org/05xcney74 |
| authorships[2].institutions[0].type | government |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210157822 |
| authorships[2].institutions[0].country_code | IT |
| authorships[2].institutions[0].display_name | Azienda Sanitaria Locale Roma 3 |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Sonia Barraco |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[3].author.id | https://openalex.org/A5008166723 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Domenico Triggiani |
| authorships[3].countries | IT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I5561750 |
| authorships[3].affiliations[0].raw_affiliation_string | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[3].institutions[0].id | https://openalex.org/I5561750 |
| authorships[3].institutions[0].ror | https://ror.org/027ynra39 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I5561750 |
| authorships[3].institutions[0].country_code | IT |
| authorships[3].institutions[0].display_name | University of Bari Aldo Moro |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Domenico Triggiani |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[4].author.id | https://openalex.org/A5096829980 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Daniele Tragni |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I5561750 |
| authorships[4].affiliations[0].raw_affiliation_string | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[4].institutions[0].id | https://openalex.org/I5561750 |
| authorships[4].institutions[0].ror | https://ror.org/027ynra39 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I5561750 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | University of Bari Aldo Moro |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Daniele Tragni |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[5].author.id | https://openalex.org/A5026806749 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-3221-6562 |
| authorships[5].author.display_name | Giuseppina Piazzolla |
| authorships[5].countries | IT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I5561750 |
| authorships[5].affiliations[0].raw_affiliation_string | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[5].institutions[0].id | https://openalex.org/I5561750 |
| authorships[5].institutions[0].ror | https://ror.org/027ynra39 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I5561750 |
| authorships[5].institutions[0].country_code | IT |
| authorships[5].institutions[0].display_name | University of Bari Aldo Moro |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Giuseppina Piazzolla |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[6].author.id | https://openalex.org/A5074195972 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-6308-0528 |
| authorships[6].author.display_name | Vincenzo Triggiani |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I5561750 |
| authorships[6].affiliations[0].raw_affiliation_string | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I5561750 |
| authorships[6].institutions[0].ror | https://ror.org/027ynra39 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I5561750 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | University of Bari Aldo Moro |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Vincenzo Triggiani |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[7].author.id | https://openalex.org/A5018284397 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-1348-3489 |
| authorships[7].author.display_name | Giovanni Carbotta |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210157822 |
| authorships[7].affiliations[0].raw_affiliation_string | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[7].institutions[0].id | https://openalex.org/I4210157822 |
| authorships[7].institutions[0].ror | https://ror.org/05xcney74 |
| authorships[7].institutions[0].type | government |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210157822 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | Azienda Sanitaria Locale Roma 3 |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Giovanni Carbotta |
| authorships[7].is_corresponding | True |
| authorships[7].raw_affiliation_strings | UOSD Diabetologia, Endocrinologia, ASL RM5, Rome, Italy |
| authorships[8].author.id | https://openalex.org/A5027919692 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6521-8578 |
| authorships[8].author.display_name | Giuseppe Lisco |
| authorships[8].countries | IT |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I5561750 |
| authorships[8].affiliations[0].raw_affiliation_string | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| authorships[8].institutions[0].id | https://openalex.org/I5561750 |
| authorships[8].institutions[0].ror | https://ror.org/027ynra39 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I5561750 |
| authorships[8].institutions[0].country_code | IT |
| authorships[8].institutions[0].display_name | University of Bari Aldo Moro |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Giuseppe Lisco |
| authorships[8].is_corresponding | True |
| authorships[8].raw_affiliation_strings | Interdisciplinary Department of Medicine, University of Bari, A. Moro, Bari, Italy |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://hdl.handle.net/11573/1691501 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2023-05-01T00:00:00 |
| display_name | Dyslipidemia and Cardiovascular Prevention in the Elderly: A Balancebetween Benefits and Risks of Statin Treatment in a Specific Population |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10394 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.98089998960495 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Lipoproteins and Cardiovascular Health |
| related_works | https://openalex.org/W2039412011, https://openalex.org/W2393378262, https://openalex.org/W2987751125, https://openalex.org/W2372035975, https://openalex.org/W1572905580, https://openalex.org/W1964550047, https://openalex.org/W2366041794, https://openalex.org/W1988062963, https://openalex.org/W3214989315, https://openalex.org/W2264994468 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:iris.uniroma1.it:11573/1691501 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4377196107 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | IRIS Research product catalog (Sapienza University of Rome) |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | info:eu-repo/semantics/article |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://hdl.handle.net/11573/1691501 |
| primary_location.id | doi:10.2174/1871530323666230428092828 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S4210179974 |
| primary_location.source.issn | 1871-5303, 2212-3873 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1871-5303 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Endocrine Metabolic & Immune Disorders - Drug Targets |
| primary_location.source.host_organization | https://openalex.org/P4310320079 |
| primary_location.source.host_organization_name | Bentham Science Publishers |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320079 |
| primary_location.source.host_organization_lineage_names | Bentham Science Publishers |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Endocrine, Metabolic & Immune Disorders - Drug Targets |
| primary_location.landing_page_url | https://doi.org/10.2174/1871530323666230428092828 |
| publication_date | 2023-05-01 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W2410722533, https://openalex.org/W2068985198, https://openalex.org/W3175194506, https://openalex.org/W2580792129, https://openalex.org/W3183857127, https://openalex.org/W2017564803, https://openalex.org/W2899742633, https://openalex.org/W3197233987, https://openalex.org/W2895778623, https://openalex.org/W1818283961, https://openalex.org/W2135631433, https://openalex.org/W2619015076, https://openalex.org/W2137983259, https://openalex.org/W2313998826, https://openalex.org/W2604860179, https://openalex.org/W4292841356, https://openalex.org/W2914546434, https://openalex.org/W1998391689, https://openalex.org/W1546258268, https://openalex.org/W4213331590, https://openalex.org/W2092170177, https://openalex.org/W2905331745, https://openalex.org/W1595104723, https://openalex.org/W1604547439, https://openalex.org/W2114350677, https://openalex.org/W2115169717, https://openalex.org/W2111487853, https://openalex.org/W2095152560, https://openalex.org/W2097870088, https://openalex.org/W4240604069, https://openalex.org/W1502524639, https://openalex.org/W2098852684, https://openalex.org/W2108165657, https://openalex.org/W181547059, https://openalex.org/W2548974574, https://openalex.org/W3185007691, https://openalex.org/W4291465177, https://openalex.org/W2547324221, https://openalex.org/W4293253252 |
| referenced_works_count | 39 |
| abstract_inverted_index.a | 156 |
| abstract_inverted_index.CV | 154 |
| abstract_inverted_index.an | 64, 193 |
| abstract_inverted_index.as | 132, 186, 204 |
| abstract_inverted_index.in | 17, 46, 66, 73, 85, 93, 100, 106, 112, 144, 167 |
| abstract_inverted_index.is | 57, 160, 202 |
| abstract_inverted_index.of | 11, 23, 38, 54, 83, 88, 104, 129, 135, 141, 152, 196, 200, 246 |
| abstract_inverted_index.on | 80, 171, 225 |
| abstract_inverted_index.to | 34, 63, 123, 177, 241 |
| abstract_inverted_index.70. | 147 |
| abstract_inverted_index.CVD | 105 |
| abstract_inverted_index.The | 52, 77 |
| abstract_inverted_index.and | 13, 30, 43, 49, 90, 108, 181, 198, 216, 250 |
| abstract_inverted_index.are | 5, 21, 31, 98, 208 |
| abstract_inverted_index.due | 176 |
| abstract_inverted_index.one | 22 |
| abstract_inverted_index.the | 7, 24, 36, 74, 81, 86, 102, 133, 150, 243 |
| abstract_inverted_index.age, | 131 |
| abstract_inverted_index.aged | 18, 168 |
| abstract_inverted_index.also | 161 |
| abstract_inverted_index.both | 47 |
| abstract_inverted_index.dose | 199 |
| abstract_inverted_index.life | 67, 136 |
| abstract_inverted_index.more | 209 |
| abstract_inverted_index.most | 8 |
| abstract_inverted_index.over | 60, 146 |
| abstract_inverted_index.risk | 37, 103, 127 |
| abstract_inverted_index.role | 82 |
| abstract_inverted_index.such | 185 |
| abstract_inverted_index.than | 213, 219 |
| abstract_inverted_index.type | 197 |
| abstract_inverted_index.used | 33 |
| abstract_inverted_index.when | 239 |
| abstract_inverted_index.with | 120, 211, 217 |
| abstract_inverted_index.(CVD) | 4 |
| abstract_inverted_index.Aims: | 76 |
| abstract_inverted_index.among | 6 |
| abstract_inverted_index.avoid | 242 |
| abstract_inverted_index.first | 244 |
| abstract_inverted_index.paper | 78 |
| abstract_inverted_index.risk, | 155 |
| abstract_inverted_index.those | 145 |
| abstract_inverted_index.time, | 61 |
| abstract_inverted_index.using | 117 |
| abstract_inverted_index.(e.g., | 222 |
| abstract_inverted_index.Before | 189 |
| abstract_inverted_index.artery | 41 |
| abstract_inverted_index.assess | 124 |
| abstract_inverted_index.before | 163 |
| abstract_inverted_index.causes | 10 |
| abstract_inverted_index.choice | 195 |
| abstract_inverted_index.events | 207, 249 |
| abstract_inverted_index.needed | 203 |
| abstract_inverted_index.people | 169 |
| abstract_inverted_index.reduce | 35 |
| abstract_inverted_index.should | 236 |
| abstract_inverted_index.statin | 142, 165, 191 |
| abstract_inverted_index.widely | 32 |
| abstract_inverted_index.Besides | 149 |
| abstract_inverted_index.Despite | 230 |
| abstract_inverted_index.Statins | 20, 97 |
| abstract_inverted_index.adverse | 206, 232 |
| abstract_inverted_index.against | 28 |
| abstract_inverted_index.burdens | 72, 92 |
| abstract_inverted_index.chronic | 55, 183 |
| abstract_inverted_index.despite | 69 |
| abstract_inverted_index.effects | 140 |
| abstract_inverted_index.elderly | 94, 234 |
| abstract_inverted_index.events, | 233 |
| abstract_inverted_index.focused | 79 |
| abstract_inverted_index.heavier | 70 |
| abstract_inverted_index.leading | 25, 62 |
| abstract_inverted_index.people. | 19 |
| abstract_inverted_index.primary | 48, 109 |
| abstract_inverted_index.receive | 237 |
| abstract_inverted_index.related | 44, 91, 251 |
| abstract_inverted_index.statins | 84, 201, 221 |
| abstract_inverted_index.Diseases | 3 |
| abstract_inverted_index.Results: | 96 |
| abstract_inverted_index.accurate | 194 |
| abstract_inverted_index.baseline | 130, 153 |
| abstract_inverted_index.burdens. | 252 |
| abstract_inverted_index.coronary | 40 |
| abstract_inverted_index.cut-offs | 122 |
| abstract_inverted_index.diabetes | 187 |
| abstract_inverted_index.diseases | 42, 56 |
| abstract_inverted_index.elderly. | 75 |
| abstract_inverted_index.focusing | 170 |
| abstract_inverted_index.frailty, | 172 |
| abstract_inverted_index.improved | 58 |
| abstract_inverted_index.increase | 65 |
| abstract_inverted_index.outcomes | 45 |
| abstract_inverted_index.patients | 235 |
| abstract_inverted_index.possible | 231 |
| abstract_inverted_index.produces | 138 |
| abstract_inverted_index.reducing | 101 |
| abstract_inverted_index.regimens | 215 |
| abstract_inverted_index.relevant | 9 |
| abstract_inverted_index.specific | 118, 157 |
| abstract_inverted_index.starting | 190 |
| abstract_inverted_index.statins, | 238 |
| abstract_inverted_index.therapy, | 192 |
| abstract_inverted_index.cognitive | 179 |
| abstract_inverted_index.encourage | 116 |
| abstract_inverted_index.essential | 99 |
| abstract_inverted_index.expansion | 134 |
| abstract_inverted_index.favorable | 139 |
| abstract_inverted_index.high-dose | 212 |
| abstract_inverted_index.high-risk | 113 |
| abstract_inverted_index.lipophile | 218 |
| abstract_inverted_index.mellitus. | 188 |
| abstract_inverted_index.morbidity | 12 |
| abstract_inverted_index.mortality | 14 |
| abstract_inverted_index.patients. | 95 |
| abstract_inverted_index.potential | 173, 205, 223 |
| abstract_inverted_index.prevalent | 210 |
| abstract_inverted_index.recurrent | 247 |
| abstract_inverted_index.secondary | 50, 107 |
| abstract_inverted_index.treatment | 143, 166 |
| abstract_inverted_index.Guidelines | 115 |
| abstract_inverted_index.algorithms | 119 |
| abstract_inverted_index.assessment | 159 |
| abstract_inverted_index.background | 182 |
| abstract_inverted_index.especially | 16 |
| abstract_inverted_index.estimation | 151 |
| abstract_inverted_index.hydrophile | 220 |
| abstract_inverted_index.individual | 125 |
| abstract_inverted_index.management | 53, 87 |
| abstract_inverted_index.nec-essary | 162 |
| abstract_inverted_index.occur-ring | 39 |
| abstract_inverted_index.occurrence | 245 |
| abstract_inverted_index.worldwide, | 15 |
| abstract_inverted_index.Conclusion: | 229 |
| abstract_inverted_index.Discussion: | 148 |
| abstract_inverted_index.age-related | 158 |
| abstract_inverted_index.cholesterol | 227 |
| abstract_inverted_index.ex-pectancy | 68 |
| abstract_inverted_index.expec-tancy | 137 |
| abstract_inverted_index.impairment, | 180 |
| abstract_inverted_index.implication | 224 |
| abstract_inverted_index.prescribing | 164 |
| abstract_inverted_index.prevention, | 110 |
| abstract_inverted_index.prevention. | 51 |
| abstract_inverted_index.age-specific | 121 |
| abstract_inverted_index.appropriate, | 240 |
| abstract_inverted_index.considerably | 59 |
| abstract_inverted_index.individuals. | 114 |
| abstract_inverted_index.interactions | 175 |
| abstract_inverted_index.irrespective | 128 |
| abstract_inverted_index.metabolism). | 228 |
| abstract_inverted_index.Introduction: | 0 |
| abstract_inverted_index.interventions | 27 |
| abstract_inverted_index.partic-ularly | 111 |
| abstract_inverted_index.Cardiovascular | 2 |
| abstract_inverted_index.cardiovascular | 126, 248 |
| abstract_inverted_index.intra-cerebral | 226 |
| abstract_inverted_index.Atherosclerotic | 1 |
| abstract_inverted_index.atherosclerosis | 29, 89 |
| abstract_inverted_index.comorbidi-ties, | 184 |
| abstract_inverted_index.pharmacological | 26, 174 |
| abstract_inverted_index.comorbidity-related | 71 |
| abstract_inverted_index.low-to-moderate-dose | 214 |
| abstract_inverted_index.polypharmacotherapy, | 178 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5018284397, https://openalex.org/A5027919692 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I4210157822, https://openalex.org/I5561750 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.84522556 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |